Re-assessment of drugs’ economic effectiveness should be reserved, KPMA says

Published: 2009-01-23 06:59:00

Updated: 2009-01-23 06:59:00

The government will have to delay its re-assessment plan over 3,000 medicines this year in the midst of business downturn, the Korea Pharmaceutical Manufacturers Association said in a statement.

In the statement co-signed by 100 pharmaceutical firms, which was delivered to the Ministry of Heal...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK